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The antiapoptotic Livin/ML-IAP gene has recently gained much attention as a potential new target for cancer therapy. Reports
indicating that livin is expressed almost exclusively in tumours, but not in the corresponding normal tissue, suggested that the targeted
inhibition of livin may present a novel tumour-specific therapeutic strategy. Here, we compared the expression of livin in renal cell
carcinoma and in non-tumorous adult kidney tissue by quantitative real-time reverse transcription-PCR, immunoblotting, and
immunohistochemistry. We found that livin expression was significantly increased in tumours (P¼0.0077), but was also clearly
detectable in non-tumorous adult kidney. Transcripts encoding Livin isoforms a and b were found in both renal cell carcinoma and
normal tissue, without obvious qualitative differences. Livin protein in renal cell carcinoma samples exhibited cytoplasmic and/or
nuclear staining. In non-tumorous kidney tissue, Livin protein expression was only detectable in specific cell types and restricted to the
cytoplasm. Thus, whereas the relative overexpression of livin in renal cell carcinoma indicates that it may still represent a therapeutic
target to increase the apoptotic sensitivity of kidney cancer cells, this strategy is likely to be not tumour-specific.
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The inhibitor of apoptosis protein (IAP) family encompasses
structurally related proteins which may contribute to the devel-
opment and therapeutic resistance of cancers (Salvesen and
Duckett, 2002). Livin, alternatively termed ML-IAP or KIAP, is
one of eight known human IAPs (Chang and Schimmer, 2007; Liu
et al, 2007). Two splicing variants of Livin, Livin a and Livin b,
have been identified which possess an identical amino-acid
sequence, except for additional 18 amino acids present only in
the a-isoform (Vucic et al, 2000; Ashhab et al, 2001). It has been
shown that targeted interference with livin expression can
resensitise tumour cells towards apoptosis (Kasof and Gomes,
2001; Crnkovic ´-Mertens et al, 2003).
Initially, a role for Livin in tumorigenesis had been proposed for
malignant melanoma (Vucic et al, 2000). More recently, however,
livin expression was also detected in various additional cancers,
including leukaemias (Qiuping et al, 2004; Choi et al, 2007),
bladder cancer (Gazzaniga et al, 2003), lung cancer (Tanabe et al,
2004; Hariu et al, 2005; Crnkovic ´-Mertens et al, 2006b),
neuroblastoma (Kim et al, 2005), nasopharyngeal carcinoma
(Xiang et al, 2006), astrocytoma (Liu et al, 2006), malignant
pleural mesothelioma (Gordon et al, 2007), pancreatic cancer
(Lopes et al, 2007), and renal cell carcinoma (RCC) (Crnkovic ´-
Mertens et al, 2007). Notably, studies of biopsies from bladder
cancer (Gazzaniga et al, 2003), lung cancer (Hariu et al, 2005),
nasopharyngeal carcinoma (Xiang et al, 2006), malignant pleural
mesothelioma (Gordon et al, 2007), and pancreatic cancer (Lopes
et al, 2007) reported that Livin is typically expressed in the tumour
samples, but not in the corresponding normal tissues. Thus, it
could be envisioned to develop the targeted inhibition of livin as a
future tumour-specific therapeutic strategy (Chang and Schimmer,
2007; Liu et al, 2007). It therefore will be of great interest to
determine the Livin status of different tumour entities in relation
to the corresponding normal tissue.
Renal cell carcinoma (RCC) is estimated to account for more
than 51000 new cases and almost 13000 cancer-related deaths in
the United States in the year 2007, making it the second most lethal
of the urological cancers (Jemal et al, 2007). Renal cell carcinomas
typically are highly resistant towards chemotherapy and possess
a poor prognosis (Flanigan et al, 2003). We recently found
that silencing of Livin-positive RCC cell lines was linked to a
re-sensitisation of the tumour cells towards proapoptotic agents,
including chemotherapeutics (Crnkovic ´-Mertens et al, 2007). To
evaluate the potential of livin to serve as a tumour-specific
therapeutic target, we here compared its expression in primary
RCC specimens and in non-tumorous tissue samples from adult
kidney. In addition, we analysed the expression of livin isoforms a
and b in tumorous and non-tumorous tissue.
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Tissue samples
Fresh-frozen tissue samples of RCC (n¼15), macroscopically and
histologically normal tissue derived from kidneys removed
because of malignant disease (n¼18), and tissue from kidneys
removed because of benign disease (n¼6) were obtained from the
tissue bank of the National Center for Tumor Diseases (NCT)
Heidelberg. These tissues included nine paired samples of tumour
and adjacent non-tumorous tissue.
Paraffin-embedded tissues encompassed RCC samples (n¼13),
normal tissue adjacent to tumour (n¼14) and kidney removed
because of benign disease (n¼3).
Tumour stage was classified according to the tumour node
metastasis staging system (Greene et al,2 0 0 2 ) .T h ew o r kw a sc o v e r e d
by a votum of the Ethical Committee of the University of Heidelberg
no. 206/2005. Written consent was obtained from each patient.
RNA extraction and quantitative real-time reverse
transcription (RT)–PCR
RNA extraction and qRT–PCR analyses were performed as
described previously (Crnkovic ´-Mertens et al, 2006b). In brief,
RNA was isolated from homogenised tissues by phenol–chloro-
form extraction. We also included a commercially available RNA
sample, representing a mixture of 14 different RNAs derived from
normal kidney, unrelated to cancer (Clontech, Mountain View, CA,
USA). Reverse transcription of 1mg RNA was performed using the
oligo-dT primer and SuperScriptIII First-Strand kit (Invitrogen,
Karlsruhe, Germany). Livin, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), and hypoxanthine phosphoribosyl-transferase 1
(HPRT1) expression were determined by real-time PCR. Relative
quantification was performed using the comparative Ct (2 DDCt)
method (Livak and Schmittgen, 2001). Data are presented as the
fold difference in gene expression normalised to a housekeeping
gene index (the geometric mean of the expression levels of GAPDH
and HPRT1), as an endogenous reference, and relative to a
calibrator sample.
Reverse transcription–PCR
Expression of livin a and b mRNAs was analysed by RT–PCR,
using primers which distinguish between the two splice variants
(Crnkovic ´-Mertens et al, 2006a). PCR products (153bp for livin a,
99bp for livin b) were analysed by agarose gel electrophoresis.
Protein extraction from fresh-frozen tissue and Western
blot analyses
Proteins were extracted from tumorous and non-tumorous adult
kidney specimens, as described previously (Crnkovic ´-Mertens
et al, 2007). Briefly, tissue sections were homogenised in lysis
buffer, supplemented with protease inhibitors and Pefabloc
(Biomol, Hamburg, Germany). Lysates were centrifuged at
100000g for 30min at 41C and supernatants collected. Proteins
were separated by 12.5% SDS–polyacrylamide gel electrophoresis,
transferred on to an Immobilon-P membrane (Millipore, Billerica,
MA, USA), and detected with a monoclonal anti-Tubulin antibody
(Oncogene, Boston, MA, USA). The hybridoma producing the
monoclonal anti-Livin antibody no. 6 was raised in a male Balb/c
mouse which was immunised by injection of purified Livin–hexa–
His fusion protein. Western blots were performed by employing
enhanced chemiluminescence (Millipore).
Immunohistochemistry
Paraffin-embedded tissue samples were cut at 2mm, placed on
slides, and dried for 24h at 371C. Sections were dewaxed,
rehydrated using xylol and descending series of ethanol, and
immersed in 3% H2O2 for 5min to block endogenic peroxidases.
After washing with TBST (50mM Tris, 300mM NaCl pH 7.6, 0.1%
Tween), unspecific antibody binding sites were blocked using
protein block solution provided by the Catalyzed Signal Amplifi-
cation (CSA) II System (DAKO, Carpinteria, CA, USA). Sections
were incubated for 30min at room temperature with a monoclonal
anti-human Livin mouse antibody (Active Motif, San Diego, CA,
USA) at a dilution of 1:400. Sections were immersed in
horseradish peroxidase-conjugated anti-mouse antibody for
15min at room temperature, followed by an incubation with
fluorescyl-tyramide hydrogen peroxide, for 15min to intensify
staining. Thereafter, sections were incubated with anti-fluorescein
antibody conjugated to horseradish peroxidase and exposed to
DAB solution (3,30-diaminobenzidine tetrahydrochloride) for
2min. Counterstaining of cell nuclei was carried out by immersing
the section in hemalaun. Sections were thoroughly washed, glass
covered, and analysed by light microscopy (Olympus Vanox-T,
Hamburg, Germany), using a magnification of up to  400. Tissue
specimens were examined at random order by two independent
examiners for the absence or presence of Livin staining in the
cytoplasm or nucleus of tumorous and non-tumorous tissues.
Statistics
Livin mRNA measurements were log transformed to achieve data,
which can be assumed to be normally distributed. To compare the
distributions of log-livin between tumour and non-tumour tissues,
a mixed linear model with the patient as random factor was
applied, to account for paired data in nine patients. The test for the
difference in log-livin between the different tissues is two-sided
with a significance level of P¼0.05. Test analysis was carried out
with the Statistical Analysis System, Version 9.1 for Windows (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Comparative analysis of Livin expression in RCCs and
non-tumorous tissue
Quantitative real-time RT–PCR analyses were performed, to
measure expression of the livin gene in (i) RCC tumour tissues,
(ii) macroscopically and histologically normal tissue derived from
kidneys removed because of malignant disease, and (iii) tissue
from kidneys removed because of benign disease. Livin transcripts
were detectable in all specimens examined. We found that livin
mRNA levels in tumour tissue were significantly higher
(P¼0.0077) than in samples from normal adult kidney tissue
(Figure 1A). Livin transcript levels in normal tissue and in
specimens from benign kidney diseases were in the same range as
was a commercially available sample representing a mixture of 14
RNAs derived from normal kidney (data not shown).
To investigate whether the difference in Livin expression
between tumorous and non-tumorous samples is reflected at the
protein level, we analysed five paired samples (tumour tissue and
adjacent normal tissue from the same patient) by direct protein
extraction from the tissues. As shown in Figure 1B, Livin protein
levels were clearly detectable in all tumour samples, but close to
the detection limit of this method in adjacent normal tissue. Taken
together, these findings demonstrate that both the livin gene and
the Livin protein are expressed in tumorous and non-tumorous
kidney tissues, with significantly increased expression in RCCs.
Analysis of Livin isoforms a and b in RCCs and
non-tumorous tissue
We analysed expression of Livin isoforms a and b by isoform-
specific RT–PCR (Crnkovic ´-Mertens et al, 2006a). Both livin a and
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sb mRNA were consistently detected. Overall, livin a and b mRNAs
expression levels were similar in 3 out of 9 tumour tissues and in 6
out of 13 non-tumorous adult kidney samples whereas 6 out of 9
tumours and 7 out of 13 non-tumorous adult kidney samples
exhibited higher livin a mRNA levels. Thus, whereas the relative
ratio between livin a and b varied for individual sample pairs, it
did not show an obvious link to tumorigenicity. Exemplary results
for five corresponding samples from non-tumorous and tumorous
tissue are shown in Figure 2.
Immunohistochemical analysis of Livin protein expression
in RCCs and non-tumorous tissue
Next, we investigated the expression of Livin protein in paraffin-
embedded tissues from RCCs and non-tumorous tissue, by
immunohistochemistry. Livin expression was detectable in 10
out of 13 RCC tissue samples (Figure 3B–D). Moreover, Livin
could be clearly visualised in all 17 specimens from non-tumorous
adult kidney (Figure 4B and C). Livin expression was restricted to
specific cells in non-tumorous kidney, namely to glomerular
mesangial cells and podocytes (Figure 4B) as well as to distal and
collect tubule epithelial cells (Figure 4B and C). Proximal tubular
cells, which are thought to be the origin of most RCCs (Campbell
et al, 2007), did not express detectable levels of Livin.
At the cellular level, Livin protein expression was detected in the
cytoplasm of renal cancer cells in 7 out of 10 positive tumour
specimens (Figure 3B). In addition, 6 out of 10 positive tumour
specimens exhibited nuclear staining for Livin, to varying degrees
(Figure 3C), which included three specimens staining positive both
in the cytoplasm and nucleus (Figure 3D). In these latter cases, the
ratio of cells with nuclear or cytoplasmic staining was approxi-
mately 30–70%. On the contrary, Livin expression in non-
tumorous adult kidney cells was always limited to the cytoplasm
(Figure 4B and C).
Taken together, these findings demonstrate that Livin is not only
expressed in a large proportion of RCCs but also to a significant
degree in specific cells of the normal kidney.
DISCUSSION
In contrast to many other ubiquitously expressed IAPs, Livin is
commonly considered to exhibit a largely tumour-specific expres-
sion pattern. This, together with the documented antiapoptotic
activity of Livin, has raised considerable interest in developing
strategies for the therapeutic inhibition of Livin in cancers (Chang
and Schimmer, 2007; Liu et al, 2007). Conceptionally, these
approaches would aim at correcting the increased apoptotic
resistance of Livin-expressing cancer cells, thereby specifically
increasing the susceptibility of tumour cells towards proapoptotic
anticancer agents. Indeed, previous studies have shown that the
targeted inhibition of livin by antisense oligonucleotides or RNA
interference reduces the growth of Livin-expressing tumour cells in
clonogenic survival assays and can resensitise them towards
proapoptotic agents, including chemotherapeutics (Kasof and
Gomes, 2001; Crnkovic ´-Mertens et al, 2003, 2006a,b, 2007).
Currently followed strategies aiming at the targeted inhibition of
Livin include inhibitory peptides and small molecules (Franklin
et al, 2003) and nucleic acid-based approaches (Crnkovic ´-Mertens
et al, 2003). Since the specificity of these approaches would greatly
profit from a tumour-specific expression of their target, we here
investigated the expression of Livin in RCC and non-tumorous
adult kidney.
Here, we demonstrate that Livin is not only expressed in RCCs,
but also clearly detectable in specific cells of normal kidney. These
findings contradict the common view that Livin expression is
largely tumour-specific. Notably, previous studies did not detect
livin expression in adult kidney by Northern blot analysis (Lin
et al, 2000; Vucic et al, 2000; Kasof and Gomes, 2001), possibly due
to the detection limit of this method. Only one RT–PCR analysis
reported weak expression of livin b, but not livin a mRNA, in a
single sample from adult kidney present in a commercially
available multiple tissue cDNA panel (Ashhab et al, 2001). This
finding was not followed further and is in contrast to our findings
which indicate expression of both isoforms in non-tumorous
tissue.
In non-tumorous kidney, highest levels of Livin protein were
detected in glomerular mesangial cells and podocytes as well in
distal and collecting tubule epithelial cells. These cells are in direct
Livin 
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Figure 2 Analysis of primary renal cell carcinomas (RCCs) and non-
tumorous adult kidney for the expression of mRNAs encoding Livin
isoforms a and b. Five paired samples of tumour (T1–5) and adjacent non-
tumorous tissue (N1–5) were analysed by isoform-specific RT–PCR. HeLa
cells, which express both isoforms (Crnkovic ´-Mertens et al, 2006a), served
as a positive control. GAPDH, internal standard.
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Figure 1 Livin mRNA and protein levels in renal cell carcinoma (RCC)
tumour tissue and non-tumorous adult kidney. (A) Livin mRNA expression
levels were measured by qRT–PCR in tissue specimens from RCC
(n¼15) and non-tumorous kidney tissue adjacent to tumour (n¼18). This
analysis included nine paired samples of tumour and corresponding non-
tumorous tissue. Values were log transformed. A mixed linear model with
the patient as a random factor was applied to account for paired data in
nine patients when comparing the distributions of log-livin between
different tissues. Log-livin measurements were visualised in box plots with
upper whiskers drawn up to the maximum value below third
quartileþ1.5* (interquartile range), lower whiskers defined accordingly,
asterisk: outlier. (B) Western blot analysis of Livin protein in five paired
samples in primary RCCs (T1–5) and non-tumorous tissue adjacent to the
tumour (N1–5). HeLa cells served as positive control for Livin expression;
Tubulin: loading control.
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scontact with urine during the filtration process. Although at
present purely speculative, one could envision that antiapoptotic
factors play a role for the protection of normal kidney cells from
toxic substances in the urine.
It is remarkable that proximal tubular cells, from which most
RCCs are believed to originate (Campbell et al, 2007), did not stain
positive for Livin. Although we cannot exclude that these cells
express low levels of Livin which are below the detection threshold
B
A
C
D
Figure 3 Immunohistochemical analysis of Livin protein expression in primary renal cell carcinomas (RCCs). (A) Negative control: RCC tissue specimen,
incubated with mouse IgG instead of the anti-Livin antibody. (B) Overview (left panel) and higher resolution (right panel) of an RCC sample showing
cytoplasmic localisation of Livin (arrows), sparing the nucleus. (C) Overview (left panel) and higher resolution (right panel) of an RCC sample showing
nuclear localisation of Livin (arrows). (D) Overview (left panel) and higher resolution of an RCC sample exhibiting both nuclear (interrupted arrow) and
cytoplasmic (arrow) staining. Higher resolved areas in the right panels correspond to the framed regions in the left panels, bars, 5mm.
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sof immunohistochemistry, the strong signals obtained in RCC cells
indicate that an increase in Livin expression is acquired during
RCC tumorigenesis. Furthermore, and in contrast to non-
tumorous kidney tissue where Livin protein expression was
restricted to the cytoplasm, we observed in 6 out of 10 positive
tumour tissues nuclear staining. This suggests that Livin may also
play a nuclear role during the transformation process. Nuclear
activities which could be relevant for cell transformation have been
demonstrated for other IAPs, such as survivin (Altieri, 2006) or
cIAP1 (Samuel et al, 2005). Moreover, nuclear staining for IAPs
has been related to the clinical prognosis of some tumours (Imoto
et al, 2002; Li et al, 2005; Gordon et al, 2007). It therefore will be
interesting to relate the subcellular localisation of Livin to the
clinical prognosis of RCC patients in future studies, which will
require higher patient numbers for statistical validation.
The significant levels of Livin expression in specific cells of
normal kidney suggest that its targeted inhibition will not be a
strictly tumour-specific therapeutic strategy. This should be taken
into account for the development of livin inhibitors, to avoid
unwanted side effects, such as nephrotoxicity. Furthermore, Livin
has been reported to be a suitable target for the immunotherapy of
lung cancer and of malignant melanoma where it can serve as a
tumour rejection antigen (Schmollinger et al, 2003; Andersen et al,
2004; Schmollinger and Dranoff, 2004; Hariu et al, 2005). These
immunotherapeutic strategies may also be complicated by
expression of the targeted antigen in normal cells. Yet, we also
would like to stress the point that our findings do not disqualify
Livin as a therapeutic target. The observed overexpression of livin
in RCCs may still allow a preferential, rather than a specific attack
on tumour cells, depending on the therapeutic index of livin
inhibitors. Accordingly, other IAPs overexpressed in cancers, such
as XIAP or survivin, are considered as potential therapeutic
targets, despite they are also expressed in normal tissues (Fukuda
and Pelus, 2006; LaCasse et al, 2006).
B
A
C
Figure 4 Immunohistochemical analysis of Livin protein expression in non-tumorous kidney. (A) Negative control: non-tumorous kidney, incubated with
mouse IgG. (B) Overview (left panel) and higher resolution (right panel) of normal kidney, showing cytoplasmic localisation of Livin in distal tubule epithelial
cells (arrow) and in glomerular mesangial cells and podocytes (interrupted arrow). (C) Overview (left panel) and higher resolution (right panel) of normal
kidney, showing cytoplasmic localisation of Livin in distal tubule epithelial cells (arrows). Higher resolved areas in the right panels correspond to the framed
regions in the left panels, bars, 5mm.
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